• Home
  • |
  • Contact
  • Add to Favorites
  • |
  • Stay up to Date
  • |
  • Tell a Colleague
  • |
  • Send us your Feedback
Skip navigation links
HOME
ABOUT EMAS
MEETINGS
MEMBERSHIP
EDUCATION
MEDIA
PATIENTS
ARCHIVES
WHO WE ARE
PRESIDENT'S LETTER
EMAS GOVERNING BOARD
HOW TO JOIN EMAS
EMAS CORPORATE MEMBERS
AFFILIATED SOCIETIES
CONTACT US
Scroll up
Scroll down
MEETINGS & EVENTS
LETTER OF INVITATION
EMAS CONGRESS
Scroll up
Scroll down
EMAS MEMBER BENEFITS
MEMBERSHIP APPLICATION FORM
MEMBERSHIP RENEWAL FORM
Scroll up
Scroll down
MATURITAS JOURNAL
EDUCATIONAL LINKS
EMAS CLINICAL UPDATES
EDUCATIONAL MATERIALS
Scroll up
Scroll down
EMAS PRESS RELEASES
EXTERNAL RELATIONS
Scroll up
Scroll down
INFORMATION ABOUT MENOPAUSE
WEB RESOURCES
PARTICIPATE IN RESEARCH STUDIES
REFERRAL LISTS
Scroll up
Scroll down
PPT PRESENTATIONS
ARTICLES
MENOPAUSE BOOKS
CONFERENCE INTERVIEWS
Scroll up
Scroll down
The European Menopause and Andropause Society
  • MATURITAS JOURNAL
  • EDUCATIONAL LINKS
  • EMAS CLINICAL UPDATES
  • EDUCATIONAL MATERIALS

 

 EMAS CLINICAL UPDATES 

2002 | 2003 | 2005 | 2006 | 2007

 

2007

FEBRUARY, 2007
EMAS 2006/2007 NEW recommendations on Postmenopausal Hormone Therapy

 

2006

MARCH, 2006
EMAS NEW recommendations on Postmenopausal Hormone Therapy

following:

Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R.Arch Intern Med. 2006 Feb 13;166(3):357-65

Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Grodstein F, Manson JE, Stampfer MJ. J Womens Health (Larchmt). 2006 Jan-Feb;15(1):35-44. 

 
2005

FEBRUARY, 2005

EMAS position paper on Postmenopausal Hormone Therapy
by courtesy of MATURITAS, vol 51/1

 

2002/2003

JULY, 2002

WHI / HERS II trial

Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)

Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy (JAMA 2002;288:49-57)

Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy (JAMA 2002;288:58-67

More Evidence, More Pessimism, editorial by Diana B. Petitti, MD  (JAMA 2002;288:99-101)

Principal Results from the Women's Health Initiative Randomized Controlled Trial 


Risks and Benefits of Estrogen Plus  Progestin in Healthy Postmenopausal Women (JAMA 2002;288:321-33)

Failure of Estrogen Plus Progestin Therapy for Prevention, editorial by Suzanne W. Fletcher and Graham A. Colditz (JAMA 2002;288:366-8)

 

Back to Top
EMAS Online EMAS Online

© 2008 EMAS-ONLINE.ORG KENES INTERNATIONAL